OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Kalshi Launches Sportsbook-Style Markets on Drug Trials and FDA Decisions

Elie G. Dib: How Long Does Maintenance Therapy Actually Need to Last?

Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC

Hope for Stomach Cancer and OncoDaily Announce Strategic Media Partnership

KEYNOTE-C93: Pembrolizumab May Replace Chemotherapy in dMMR Endometrial Cancer

Asparaginase Drug Monitoring in Pediatric ALL: The Brazilian Experience - Resonance

TOPAZ-1 Post Hoc Analysis: Durvalumab Plus GemCis in Advanced Biliary Tract Cancer

Four-Arc Coplanar VMAT Emerges as a Practical Option for Hippocampal-Sparing Whole-Brain Radiotherapy

Calculators

CTCAE v6.0 Adverse Events Grader

Grade adverse events based on CTCAE v6.0 criteria. Select an adverse event and enter the lab value or clinical finding to determine the severity grade (1-5).

Enter the lab value or clinical finding

CTCAE v6.0 Grade Scale:

  • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
  • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL.
  • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
  • Grade 4: Life-threatening consequences; urgent intervention indicated.
  • Grade 5: Death related to AE.